Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
P/E Ratio
--
P/B Ratio
0.78
Industry P/E
--
Debt to Equity
--
ROE
0 %
ROCE
0.04 %
Div. Yield
0 %
Book Value
3.87
EPS
0
CFO
$-134.94 Mln
EBITDA
$-143.33 Mln
Net Profit
$-151.91 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lipocine (LPCN)
| -38.52 | -10.45 | -32.58 | -36.97 | -44.99 | -18.31 | -31.79 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Lipocine (LPCN)
| 74.11 | -58.74 | -59.84 | -27.13 | 253.34 | -70.39 | -62.01 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone... replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which is in phase 3clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. Address: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 Read more
Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Dr. Mahesh V. Patel Ph.D.
Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Dr. Mahesh V. Patel Ph.D.
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lipocine Inc (LPCN) stood at $ 23 Mln as on 31-Dec-24
The share price of Lipocine Inc (LPCN) is $3.00 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Lipocine Inc (LPCN) has given a return of -44.99% in the last 3 years.
Lipocine Inc (LPCN) has a market capitalisation of $ 16 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lipocine Inc (LPCN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lipocine Inc (LPCN) and enter the required number of quantities and click on buy to purchase the shares of Lipocine Inc (LPCN).
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which is in phase 3clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. Address: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108
The CEO & director of Dr. Mahesh V. Patel Ph.D.. is Lipocine Inc (LPCN), and CFO & Sr. VP is Dr. Mahesh V. Patel Ph.D..
There is no promoter pledging in Lipocine Inc (LPCN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Lipocine Inc. (LPCN) | Ratios |
|---|---|
|
Return on equity(%)
|
0.04
|
|
Operating margin(%)
|
-10.31
|
|
Net Margin(%)
|
0.07
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lipocine Inc (LPCN) was $0 Mln.
$-0.01
(
